Picard Medical, Inc. Shareholder Class Action Lawsuit
February 9, 2026 — The law firm of Federman & Sherwood, a national plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, today announced it has commenced an independent investigation into potential securities law violations by Picard Medical, Inc. (“Picard Medical” or the “Company”) (NYSE: PMI) on behalf of purchasers of the Company’s common stock during the period between September 2, 2025 and October 31, 2025.
Details of the Investigation:
Federman & Sherwood’s investigation focuses on whether Picard Medical and certain of its officers, directors, or affiliated parties made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s business, trading activity, and the price of its securities.
The investigation will examine whether the Company was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals, whether insiders or affiliates used offshore or nominee accounts to facilitate coordinated dumping of shares during an alleged price inflation campaign, and whether the Company’s public statements and risk disclosures omitted mention of these activities or other material risks that could affect trading and investor decisions.
The inquiry also will assess whether adverse information about these matters was timely and fully disclosed to the investing public, and whether subsequent disclosures or market adjustments resulted in losses for investors who purchased or held Picard Medical stock during the relevant period.
Background:
Picard Medical, Inc. is a medical device company engaged in the design, development, production, and sale of medical device products. The Company’s common stock is publicly traded, and recent developments involving allegations of manipulation and undisclosed trading activity have raised questions regarding the completeness and accuracy of disclosures made to investors.
What This Means for Investors:
Investors who purchased or otherwise acquired Picard Medical, Inc. common stock during the relevant period and believe they suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
CONTACT FEDERMAN & SHERWOOD
Attorney Sara Collier is widely regarded as a leading attorney in the field of derivative shareholder litigation. She is driven by a deep commitment to ensuring that boards of directors and corporate executives of publicly traded companies answer to the shareholders they serve.
With over ten years of experience pursuing derivative cases nationwide—particularly in Delaware, the home jurisdiction for many major corporations—Ms. Collier has developed a reputation for skillfully pushing even the largest companies toward stronger transparency and accountability in their corporate governance.
Phone: (405) 235-1560
Email : sec@federmanlaw.com
*This is for information purposes and is not a solicitation.